InspireMD, Inc.
NSPRInspireMD, Inc. in brief
InspireMD, Inc. is a listed company in the Medical Devices industry, based in Israel. Its market value was $24 M on 30 October 2026, which makes it the 23,718th largest listed company in the world and the 253rd largest in Israel on this site. In the year to December 2025 it had sales of $9 M and a net loss of $49 M. It employs about 127 people and Marvin Slosman is its chief executive. By market, the largest shares of its 2025 sales came from USA (16%), Germany (14%) and Italy (14%). Its shares trade under the symbol NSPR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About InspireMD, Inc.
We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Our portfolio includes two commercial products based on our proprietary CGuard carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow.
Our first product, the CGuard Carotid Embolic Prevention System, integrates a self-expanding nitinol stent with a MicroNet mesh sleeve as a single device for carotid artery revascularization. In January 2024, we received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation. Our CGuard EPS previously held CE Mark approval under the former Medical Device Directive. CGuard EPS is marketed in over 30 countries outside the United States through a network of distributors.
From the company's annual report filed with the US SEC: read the report
InspireMD, Inc. timeline
- 2009
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed InspireMD, Inc.Formerly Saguaro Resources, Inc..
- 2025
- 💰Record revenue of $9 millionFY2025, the highest of the 8 years on record.
Events of InspireMD, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #399 (Jan 2020) · #361 (Jan 2021) · #451 (Jan 2022) · #425 (Dec 2022) · #298 (Jul 2023) · #315 (Jan 2024) · #36 (Mar 2026) · #239 (Aug 2026) · #253 (Oct 2026) · #253 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.2×
- Price / book
- 0.4×
- Free cash flow yield
- -150.9%
- Net margin (TTM)
- -484.1%
- Operating margin
- -552.4%
- Return on equity
- -95.1%
- Liabilities / assets
- 20.5%
- Net debt
- $-2M
- Revenue growth
- +28.1%
- R&D / revenue
- 167.0%
- Revenue per employee
- $71 K
- Profit per employee
- $-384 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $9M | +28.1% | $-50M | $-49M | -543.3% |
| Dec 2024 | $7M | +13.1% | $-34M | $-32M | -456.5% |
| Dec 2023 | $6M | +19.9% | $-21M | $-20M | -321.3% |
| Dec 2022 | $5M | +14.9% | $-19M | $-18M | -357.6% |
| Dec 2021 | $5M | +81.5% | $-15M | $-15M | -331.6% |
| Dec 2020 | $2M | -33.3% | $-10M | $-11M | -425.0% |
| Dec 2019 | $4M | +3.3% | $-10M | $-10M | -269.9% |
| Dec 2018 | $4M | — | $-8M | $-7M | -201.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-35M | $2M | $-37M | $-0.76 | — |
| Dec 2024 | $-22M | $1M | $-23M | $-0.76 | — |
| Dec 2023 | $-16M | $0M | $-17M | $-0.82 | — |
| Dec 2022 | $-16M | $0M | $-16M | $-2.35 | — |
| Dec 2021 | $-13M | $0M | $-14M | $-2.03 | — |
| Dec 2020 | $-9M | $0M | $-9M | $-6.97 | — |
| Dec 2019 | $-10M | $0M | $-10M | $-4.80 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-16.67 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $2M (-0.6% on a year earlier), net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Other events
- Nov 12, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 21, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Aug 17, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 29, 20268-KCurrent reportDirectors or officers changed
- Jul 23, 20268-KCurrent reportListing notice
- Jul 2, 20268-KCurrent reportDirectors or officers changed
- Jun 11, 20268-KCurrent reportRegulation FD disclosure
- Jun 3, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 22, 20268-KCurrent reportDirectors or officers changed
- May 7, 202610-QQuarterly report · period to Mar 2026
Official filings of InspireMD, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $9 M
- Operating income
- $-50 M
- Net income
- $-49 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $69 M
- Total liabilities
- $14 M
- Total equity
- $55 M
As of December-2025
Top 39 institutional investors in InspireMD, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 3,905,743 | 0 (0.00%) | 8.40% | $3 M | Nov 16, 2026 |
| 2 | Aberdeen Group plc | 3,698,364 | 0 (0.00%) | 7.96% | $2 M | Nov 10, 2026 |
| 3 | Nantahala Capital Management, LLC | 3,376,484 | -3,376,484 (-50.00%) | 7.26% | $2 M | Nov 13, 2026 |
| 4 | Orbimed Advisors LLC | 3,133,405 | 0 (0.00%) | 6.74% | $2 M | Nov 16, 2026 |
| 5 | Parkman Healthcare Partners LLC | 2,416,518 | 0 (0.00%) | 5.20% | $2 M | Nov 16, 2026 |
| 6 | Marshall Wace, LLP | 1,860,405 | 0 (0.00%) | 4.00% | $1 M | Nov 13, 2026 |
| 7 | Soleus Capital Management, L.P. | 1,045,708 | 0 (0.00%) | 2.25% | $1 M | Nov 16, 2026 |
| 8 | Velan Capital Investment Management LP | 924,680 | +776,542 (+524.20%) | 1.99% | $1 M | Nov 16, 2026 |
| 9 | Ingalls & Snyder LLC | 362,550 | -6,250 (-1.69%) | 0.78% | $0 M | Nov 12, 2026 |
| 10 | Affiance Financial, LLC | 250,370 | 0 (0.00%) | 0.54% | $0 M | Oct 15, 2026 |
| 11 | UBS Group AG | 133,653 | +128,339 (+2415.11%) | 0.29% | $0 M | Nov 10, 2026 |
| 12 | BlackRock, Inc. | 117,708 | -5,285 (-4.30%) | 0.25% | $0 M | Nov 13, 2026 |
| 13 | Creative Planning | 108,964 | 0 (0.00%) | 0.23% | $0 M | Nov 2, 2026 |
| 14 | Schonfeld Strategic Advisors LLC | 100,201 | +926 (+0.93%) | 0.22% | $0 M | Nov 16, 2026 |
| 15 | Renaissance Technologies LLC | 87,892 | -24,940 (-22.10%) | 0.19% | $0 M | Nov 12, 2026 |
| 16 | Courier Capital LLC | 30,000 | 0 (0.00%) | 0.06% | $0 M | Oct 19, 2026 |
| 17 | Mesirow Financial Investment Management, Inc. | 30,000 | 0 (0.00%) | 0.06% | $0 M | Nov 5, 2026 |
| 18 | Centiva Capital, LP | 27,180 | -16,943 (-38.40%) | 0.06% | $0 M | Nov 13, 2026 |
| 19 | Vestia Personal Wealth Advisors | 24,425 | 0 (0.00%) | 0.05% | $0 M | Oct 20, 2026 |
| 20 | Millennium Management LLC | 21,760 | -15,917 (-42.25%) | 0.05% | $0 M | Nov 16, 2026 |
| 21 | XTX Topco Ltd | 21,080 | -27,949 (-57.01%) | 0.05% | $0 M | Nov 16, 2026 |
| 22 | Jane Street Group, LLC | 20,402 | New | 0.04% | $0 M | Nov 12, 2026 |
| 23 | Morgan Stanley | 20,371 | -8,000 (-28.20%) | 0.04% | $0 M | Nov 13, 2026 |
| 24 | Cambridge Investment Research Advisors, Inc. | 20,116 | -20,216 (-50.12%) | 0.04% | $0 M | Nov 2, 2026 |
| 25 | HRT Financial LP | 19,346 | -40,408 (-67.62%) | 0.04% | $0 M | Nov 13, 2026 |
Show all 39: investors 26 to 39
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Susquehanna International Group, LLP | 19,100 | -1,494 (-7.25%) | 0.04% | $0 M | Nov 16, 2026 |
| 27 | Citadel Advisors LLC | 18,916 | New | 0.04% | $0 M | Nov 16, 2026 |
| 28 | LPL Financial LLC | 18,621 | 0 (0.00%) | 0.04% | $0 M | Nov 6, 2026 |
| 29 | Osaic Holdings, Inc. | 15,952 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 30 | Avestar Capital, LLC | 15,000 | 0 (0.00%) | 0.03% | $0 M | Oct 28, 2026 |
| 31 | Pallas Capital Advisors LLC | 11,000 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 32 | McKinley Carter Wealth Services, Inc. | 10,000 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 33 | BFC Planning, Inc. | 8,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 34 | Farther Finance Advisors, LLC | 1,000 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 35 | Citigroup Inc | 400 | +399 (+39900.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 36 | Royal Bank Of Canada | 247 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 37 | Tower Research Capital LLC (TRC) | 34 | New | 0.00% | $0 M | Nov 16, 2026 |
| 38 | Harbour Investments, Inc. | 14 | New | 0.00% | $0 M | Nov 9, 2026 |
| 39 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding InspireMD, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 1.74 M | $1 M | — | 0.09% | +16% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc. | 1.26 M | $1 M | — | 0.11% | +19% | Jun 30, 2026 |
| 🇺🇸 abrdn World Healthcare Fundabrdn Inc. | 695,460 | $0 M | — | 0.09% | +14% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 114,832 | $0 M | — | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 18,244 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 8,161 | $0 M | — | <0.01% | +51% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at InspireMD, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gary S. RoubinDirector | Buy | +153,846 | $0.650 | $100 K | 988,324 | Form 4 |
| filed | Marvin SlosmanCEO and President, Director | Buy | +46,154 | $0.650 | $30 K | 3.60 M | Form 4 |
| filed | Michael BermanDirector | Buy | +76,923 | $0.650 | $50 K | 429,509 | Form 4 |
| filed | Michael A. LawlessChief Financial Officer | Buy | +115,385 | $0.650 | $75 K | 807,080 | Form 4 |
| filed | Paul StukaDirector | Buyindirect | +307,693 | $0.650 | $200 K | 731,397 | Form 4 |
| filed | Paul StukaDirector | Buy | +20,000 | $0.880 | $18 K | 667,871 | Form 4 |
| filed | Shane Thomas GleasonChief Commercial Officer | Sell | -22,778 | $1.010 | $23 K | 1.05 M | Form 4 |
| filed | Paul StukaDirector | Buy | +5,000 | $1.150 | $6 K | 647,871 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: InspireMD, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 1-for-4 reverse split
Fails to deliver
- : 30,020 shares at $0.45
- : 30,020 shares at $0.47
- : 30,020 shares at $0.46
- : 30,020 shares at $0.45
- : 30,020 shares at $0.45
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
InspireMD, Inc. scorecard#
Passes 7 of the 20 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.4×Price to book 0.4× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median2.2×Price to sales 2.2× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-150.9%Free cash flow is -150.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year28.1%Revenue up 28.1% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years20.2%20.2% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median20.2%20.2% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.76 vs -0.76Diluted EPS -0.76 in fiscal 2025 against -0.76 the year before (report's currency).
- ✗Net income higher than five years earlier-$49 M-$49 M in fiscal 2025 against -$11 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$49 MNet income -$49 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-552.5%-552.5% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-106.9%-106.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-552.5%-552.5% in fiscal 2025 against -361.9% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.7×Current ratio 5.74 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.42Z-score -6.42 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year53.4%Diluted shares up 53.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from InspireMD, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -552.5% | -8.2% | |
| Net margin | -543.3% | -10.4% | |
| Return on equity | -106.9% | -16.8% | |
| Revenue growth, 3 years a year | 20.2% | 10.8% | |
| Revenue growth | 28.1% | 10.4% | |
| Free cash flow margin | -409.4% | -1.9% |
3of 8on the Piotroski tests of financial strength
- Net loss of $49 million, the 14th loss-making year in a row.
- Free cash flow was negative: -$37 million.
- The share count rose 53.4% in the year.
- Revenue has grown 5 years in a row.
InspireMD, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 9.0+28.1%100% | 7.0+13.0%100% | 6.2+20.0%100% | 5.2+15.0%100% | 4.5+80.9%100% | 2.5−33.2%100% | 3.7+3.3%100% | 3.6+30.4%100% | 2.8+45.8%100% | 1.9—100% | |
| Cost of revenue | 6.3+15.0%70.5% | 5.5+25.1%78.5% | 4.4+8.5%70.9% | 4.1+8.4%78.4% | 3.7+55.7%83.2% | 2.4−19.0%96.7% | 3.0+13.8%79.7% | 2.6+19.8%72.4% | 2.2+21.4%78.8% | 1.8—94.6% | |
| Gross profit | 2.6+75.9%29.5% | 1.5−16.7%21.5% | 1.8+61.8%29.1% | 1.1+48.1%21.6% | 0.8+808%16.8% | 0.1−89.0%3.3% | 0.8−24.0%20.3% | 1.0+70.1%27.6% | 0.6+474%21.2% | 0.1—5.4% | |
| Research and development | 15+10.0%167% | 14+70.8%195% | 8.0+2.2%129% | 7.8+51.4%151% | 5.2+131%115% | 2.2−24.4%89.9% | 3.0+92.4%79.4% | 1.5+20.3%42.6% | 1.3−1.2%46.2% | 1.3—68.2% | |
| Selling and marketing | 17+173%184% | 6.1+57.0%86.6% | 3.9+5.5%62.3% | 3.7+26.0%70.9% | 2.9+38.2%64.7% | 2.1−12.2%84.6% | 2.4+6.9%64.4% | 2.2−4.9%62.2% | 2.4+61.5%85.4% | 1.5—77.0% | |
| General and administrative | 21+35.3%231% | 15+37.8%218% | 11+32.9%179% | 8.4+12.8%162% | 7.4+20.9%165% | 6.1+17.3%247% | 5.2+8.1%140% | 4.8−6.8%134% | 5.2+3.7%188% | 5.0—264% | |
| Operating expenses | 52+49.3%582% | 35+52.5%499% | 23+15.7%370% | 20+28.2%383% | 15+47.9%344% | 10−1.0%421% | 11+22.8%284% | 8.6−2.4%239% | 8.8+13.8%319% | 7.8—409% | |
| Operating income | −50—−553% | −34—−478% | −21—−341% | −19—−362% | −15—−327% | −10—−418% | −9.8—−264% | −7.6—−211% | −8.2—−298% | −7.6—−404% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0.1−83.5%4.3% | 0.7—38.1% | |
| Other non-operating income (expense) | 0.9−42.8%9.9% | 1.6+20.5%22.2% | 1.3+417%20.8% | 0.3—4.8% | −0.2—−3.5% | −0.2—−6.4% | −0.2r0.2—−5.4% | −0.4—−10.3% | — | — | |
| Income before tax | −49—−543% | −32—−456% | −20—−320% | −18—−357% | −15—−331% | −11—−424% | −10—−269% | −7.2—−201% | −8.4—−305% | −8.5—−447% | |
| Income tax | 0.1+6.8%0.7% | 0.1−9.2%0.8% | 0.1+132%1.0% | 0.0−37.8%0.5% | 0.0+1025%1.0% | 0.0−83.3%0.2% | 0.0—0.6% | — | 0.0+2600%1.0% | 0.0—0.1% | |
| Net income including minority interests | — | — | — | — | — | — | −10—−270% | −7.7—−214% | −13—−472% | −8.5—−447% | |
| Net income attributable to shareholders | −49—−543% | −32—−457% | −20—−321% | −18—−358% | −15—−332% | −11—−424% | −10—−270% | −7.2—−201% | −8.4—−306% | −8.5—−447% | |
| Earnings per share, basic | -0.76—— | -0.76—— | -0.82—— | -2.35—— | -2.03—— | -6.97r-0.46—— | -4.80—— | -16.67r-0.33—— | -34.98—— | -207.72r-5.93—— | |
| Earnings per share, diluted | -0.76—— | -0.76—— | -0.82—— | -2.35—— | -2.03—— | -6.97r-0.46—— | -4.80—— | -16.67r-0.33—— | -34.98—— | -207.72r-5.93—— | |
| Shares, weighted average (basic) | 64+53.4%— | 42+72.8%— | 24+208%— | 7.9+7.2%— | 7.3—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 64+53.4%— | 42+72.8%— | 24+208%— | 7.9+7.2%— | 7.3+386%— | 1.5r23−27.6%— | 2.1+353%— | 0.5r23+23.9%— | 0.4+814%— | 0.0r1.4—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.9−52.7%12.9% | 19+96.2%40.4% | 9.6+108%20.2% | 4.6−61.4%18.8% | 12−5.1%30.2% | 13+129%71.1% | 5.5−41.2%55.8% | 9.4+153%76.4% | 3.7−50.6%60.7% | 7.5—79.9% | |
| Short-term investments | 45+188%65.2% | 16−46.5%33.6% | 29—61.7% | — | — | — | — | — | — | — | |
| Receivables | 2.2+37.9%3.1% | 1.6−12.9%3.4% | 1.8+74.5%3.8% | 1.0−15.5%4.2% | 1.2+157%3.1% | 0.5−42.2%2.7% | 0.8+14.9%8.3% | 0.7+11.4%5.8% | 0.6+80.6%10.5% | 0.4—3.8% | |
| Inventory | 3.4+32.1%4.9% | 2.6+22.0%5.5% | 2.1+29.9%4.4% | 1.6+41.8%6.6% | 1.1−19.2%2.9% | 1.4+14.5%8.0% | 1.2+9.0%12.5% | 1.1+113%9.2% | 0.5+6.6%8.7% | 0.5—5.3% | |
| Current assets | 61+51.7%88.6% | 41−8.2%86.6% | 44+107%92.7% | 21−42.5%86.5% | 37+142%93.4% | 15+96.4%86.3% | 7.8−31.6%79.0% | 11+122%92.9% | 5.2−40.3%84.4% | 8.6r8.6—91.7% | |
| Property, plant and equipment | 3.6+51.2%5.2% | 2.4+124%5.1% | 1.1+15.6%2.2% | 0.9+45.1%3.7% | 0.6+41.1%1.6% | 0.4−18.1%2.5% | 0.5+29.9%5.5% | 0.4−11.6%3.4% | 0.5+25.6%7.8% | 0.4—4.0% | |
| Right-of-use (leased) assets | 2.8+16.9%4.0% | 2.4+60.2%5.0% | 1.5−5.2%3.1% | 1.6+43.8%6.3% | 1.1−14.5%2.7% | 1.3+35.0%7.1% | 0.9—9.5% | — | — | — | |
| Non-current assets | 7.9+26.2%11.4% | 6.3+80.4%13.4% | 3.5+4.7%7.3% | 3.3+27.1%13.5% | 2.6+7.4%6.6% | 2.4+17.8%13.7% | 2.1+138%21.0% | 0.9−8.7%7.1% | 1.0+22.4%15.6% | 0.8r0.8—8.3% | |
| Total assets | 69+48.3%100% | 47−1.8%100% | 48+93.3%100% | 25−37.9%100% | 40+123%100% | 18+79.9%100% | 9.9−19.6%100% | 12+101%100% | 6.1−35.1%100% | 9.4—100% | |
| Accounts payable | 1.3+0.1%1.8% | 1.3+33.5%2.7% | 0.9+42.5%2.0% | 0.7−26.2%2.7% | 0.9+278%2.2% | 0.2−63.5%1.3% | 0.6−30.5%6.5% | 0.9+183%7.6% | 0.3−46.9%5.4% | 0.6—6.6% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | 2.7—28.5% | |
| Current liabilities | 11+39.5%15.4% | 7.7+27.5%16.4% | 6.0+18.7%12.6% | 5.1+16.6%20.6% | 4.3+17.3%10.9% | 3.7+18.9%20.8% | 3.1+6.7%31.5% | 2.9+17.6%23.8% | 2.5−48.1%40.6% | 4.8—50.8% | |
| Lease liabilities (non-current) | 2.2+23.8%3.2% | 1.8+73.0%3.8% | 1.0−13.1%2.2% | 1.2+53.0%4.8% | 0.8−21.8%2.0% | 1.0+53.0%5.6% | 0.7—6.6% | — | — | — | |
| Non-current liabilities | 3.5+14.7%5.0% | 3.0+43.4%6.5% | 2.1−3.1%4.5% | 2.2+19.5%8.9% | 1.8−4.0%4.6% | 1.9+38.1%10.7% | 1.4+128%14.0% | 0.6−3.0%4.9% | 0.6+6.3%10.2% | 0.6—6.2% | |
| Total liabilities | 14+32.5%20.5% | 11+31.7%22.9% | 8.1+12.1%17.1% | 7.3+17.5%29.4% | 6.2+10.1%15.6% | 5.6+24.8%31.6% | 4.5+27.6%45.5% | 3.5+13.5%28.7% | 3.1−42.1%50.9% | 5.4—57.0% | |
| Retained earnings | −302—−436% | −254—−542% | −222—−465% | −202—−818% | −183—−461% | −168—−946% | −158—−1595% | −148—−1201% | −140—−2298% | −132—−1402% | |
| Shareholders' equity | 55+53.0%79.5% | 36−8.6%77.1% | 40+127%82.9% | 17−48.1%70.6% | 34+176%84.4% | 12+126%68.4% | 5.4−38.6%54.5% | 8.8+221%71.3% | 2.7−32.6%44.7% | 4.0—43.0% | |
| Total liabilities and equity | 69+48.3%100% | 47−1.8%100% | 48+93.3%100% | 25−37.9%100% | 40+123%100% | 18+79.9%100% | 9.9−19.6%100% | 12+101%100% | 6.1−35.1%100% | 9.4—100% | |
| Shares outstanding | 44+63.6%— | 27+21.8%— | 22+162%— | 8.3+0.4%— | 8.3+153%— | 3.3r49−16.1%— | 3.9−89.8%— | 38r38+2488%— | 1.5r1.5+3378%— | 0.0r1.5—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 476+70.0%5301% | 280+20.7%3995% | 232+23.4%3739% | 188r0.2+116670%3636% | 0.2+6.6%3.6% | 0.2−4.4%6.1% | 0.2+13.7%4.2% | 0.1−9.2%3.9% | 0.2+7.7%5.5% | 0.1—7.5% | |
| Share-based compensation | 12+21.6%137% | 10+126%145% | 4.5+90.9%72.4% | 2.4+49.2%45.5% | 1.6+160%35.1% | 0.6+86.5%24.4% | 0.3+364%8.7% | 0.1−89.6%1.9% | 0.7−31.3%24.3% | 1.0—51.6% | |
| Cash from operating activities | −35—−391% | −22—−312% | −16—−264% | −16—−301% | −13—−294% | −9.1—−365% | −9.8—−264% | −7.6—−211% | −8.1—−294% | −7.5—−396% | |
| Capital expenditure | −1.7—−18.5% | −1.4—−20.0% | −0.4—−6.1% | −0.5—−9.1% | −0.3—−7.7% | −0.1—−3.5% | −0.3—−7.6% | −0.1—−1.9% | −0.3—−9.3% | −0.0—−2.6% | |
| Cash from investing activities | −31−342%−340% | 13—180% | −16−291%−259% | 8.4—163% | −22—−500% | −0.2—−7.5% | −0.4—−10.4% | −0.0—−1.2% | −0.3−554%−11.5% | 0.1—3.7% | |
| Debt repaid | — | — | — | — | — | — | — | — | −2.2—−78.9% | −2.6—−140% | |
| Shares issued | 1.00.0%11.1% | 1.0—14.3% | — | — | — | — | 6.3−61.3%170% | 16+140%455% | 6.8−52.5%247% | 14—758% | |
| Cash from financing activities | 56+201%619% | 18−50.8%263% | 38—605% | −0.1−100%−2.7% | 35+114%779% | 16+159%660% | 6.3−52.6%170% | 13+189%371% | 4.6−60.4%168% | 12—618% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 0.0—0.4% | −0.0—−1.0% | |
| Change in cash | −10.0−208%−111% | 9.3+85.2%132% | 5.0—80.7% | −7.4—−143% | −0.6−109%−14.3% | 7.1—287% | −3.9−168%−104% | 5.7—158% | −3.8−189%−138% | 4.3—225% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 11+53.4%100% | 1.8−0.4%100% | 3.4+122%100% | 3.1*+61.6%100% | 2.5+39.4%100% | 1.8+2.2%100% | 1.5+1.2%100% | 1.9*+10.7%100% | 1.8+16.3%100% | 1.7—100% | 1.5—100% | 1.8*—100% | 1.6—100% | |
| Cost of revenue | 8.9+59.3%81.9% | 2.5+73.7%144% | 2.7+119%79.8% | 2.0*+33.0%62.5% | 1.7+18.8%65.8% | 1.5+4.0%82.4% | 1.2+1.5%80.9% | 1.5*+17.8%75.9% | 1.4+24.9%77.1% | 1.4—81.0% | 1.2—80.7% | 1.3*—71.3% | 1.1—71.9% | |
| Gross profit | 2.0+31.5%18.1% | −0.8−347%−43.7% | 0.7+135%20.2% | 1.2*+152%37.5% | 0.9+109%34.2% | 0.3−5.4%17.6% | 0.30.0%19.1% | 0.5*−7.1%24.1% | 0.4−5.5%22.9% | 0.3—19.0% | 0.3—19.3% | 0.5*—28.7% | 0.4—28.1% | |
| Research and development | 16+4.3%149% | 4.3+12.0%243% | 4.8+17.3%140% | 3.5*−5.9%110% | 3.6−7.2%144% | 3.8+12.7%216% | 4.1+54.6%265% | 3.7*+81.5%189% | 3.9+85.5%216% | 3.4—196% | 2.6—174% | 2.0*—116% | 2.1—136% | |
| Selling and marketing | 20+94.3%185% | 5.2+25.1%295% | 5.2+88.4%152% | 5.2*+174%166% | 4.4+198%174% | 4.2+189%235% | 2.8+122%180% | 1.9*+46.3%98.3% | 1.5+68.0%81.3% | 1.4—83.1% | 1.2—81.9% | 1.3*—74.3% | 0.9—56.3% | |
| General and administrative | 19+7.4%178% | 4.2−22.0%235% | 4.7−4.5%139% | 4.6*+7.6%144% | 5.9+68.8%233% | 5.3+42.2%300% | 4.9+28.6%323% | 4.2*+42.4%217% | 3.5+12.9%193% | 3.7—215% | 3.8—254% | 3.0*—169% | 3.1—199% | |
| Operating expenses | 56+26.8%512% | 14+2.5%772% | 15+24.8%432% | 13*+34.9%421% | 14+56.8%552% | 13+55.2%750% | 12+52.5%769% | 9.8*+55.8%505% | 8.9+46.1%490% | 8.6—494% | 7.7—510% | 6.3*—358% | 6.1—391% | |
| Operating income | −54—−494% | −14—−816% | −14—−411% | −12*—−384% | −13—−517% | −13—−732% | −11—−750% | −9.4*—−481% | −8.5—−468% | −8.3—−475% | −7.4—−491% | −5.8*—−330% | −5.6—−362% | |
| Other non-operating income (expense) | 1.1+15.5%10.5% | 0.1—6.8% | 0.3−1.7%8.5% | 0.4*+53.2%12.3% | 0.3−40.0%13.6% | −0.1−138%−7.4% | 0.3−23.0%19.2% | 0.3*−46.2%12.9% | 0.6+24.1%31.6% | 0.4—20.2% | 0.4—25.3% | 0.5*—26.6% | 0.5—29.6% | |
| Net income attributable to shareholders | −52—−484% | −14—−809% | −14—−403% | −12*—−373% | −13—−504% | −13—−740% | −11—−730% | −9.2*—−471% | −7.9—−436% | −7.9—−455% | −7.0—−465% | −5.4*—−307% | −5.2—−333% | |
| Earnings per share, basic | — | -0.17—— | -0.16−173%— | — | -0.17—— | -0.26—— | 0.22r-0.22—— | — | -0.16—— | -0.22—— | -0.21—— | — | -0.15—— | |
| Earnings per share, diluted | — | -0.17—— | -0.16−173%— | — | -0.17—— | -0.26—— | 0.22r-0.22—— | — | -0.16—— | -0.22—— | -0.21—— | — | -0.15—— | |
| Shares, weighted average (basic) | 85+66.0%— | 85+66.0%— | 84+67.6%— | — | 73+51.9%— | 51+42.2%— | 50+46.0%— | — | 48+42.3%— | 36—— | 34—— | — | 34—— | |
| Shares, weighted average (diluted) | 85+66.0%— | 85+66.0%— | 84+67.6%— | — | 73+51.9%— | 51+42.2%— | 50+46.0%— | — | 48+42.3%— | 36—— | 34—— | — | 34—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 15—33.9% | 15+31.6%33.9% | 11−8.2%20.1% | 8.9−52.7%12.9% | 63+301%80.8% | 12−59.5%34.5% | 12+31.9%32.0% | 19+96.2%40.4% | 16+14.3%31.3% | 28—51.0% | 9.4—22.3% | 9.6—20.2% | 14—27.7% | |
| Short-term investments | 15—34.2% | 15+94.2%34.2% | 30+120%53.5% | 45+188%65.2% | — | 7.9−58.1%23.6% | 14−44.2%35.4% | 16−46.5%33.6% | 25−15.7%48.7% | 19—33.7% | 25—58.4% | 29—61.7% | 29—58.3% | |
| Receivables | 1.8—4.1% | 1.8+14.1%4.1% | 2.4+50.7%4.2% | 2.2+37.9%3.1% | 2.0+28.2%2.5% | 1.6+21.8%4.8% | 1.6+33.1%4.1% | 1.6−12.9%3.4% | 1.5+46.4%3.0% | 1.3—2.3% | 1.2—2.8% | 1.8—3.8% | 1.0—2.1% | |
| Inventory | 2.7—6.1% | 2.7−11.6%6.1% | 3.0+7.6%5.4% | 3.4+32.1%4.9% | 3.6+47.5%4.6% | 3.1+38.4%9.2% | 2.8+19.6%7.3% | 2.6+22.0%5.5% | 2.4+32.4%4.8% | 2.2—4.0% | 2.4—5.6% | 2.1—4.4% | 1.8—3.7% | |
| Current assets | 37—82.1% | 37+43.8%82.1% | 49+51.2%86.1% | 61+51.7%88.6% | 70+51.7%89.7% | 25−50.9%76.4% | 32−16.5%83.1% | 41−8.2%86.6% | 46−0.7%91.9% | 52—93.1% | 39—91.6% | 44—92.7% | 47—93.4% | |
| Property, plant and equipment | 3.9—8.6% | 3.9+24.4%8.6% | 3.7+33.4%6.5% | 3.6+51.2%5.2% | 3.4+74.9%4.3% | 3.1+94.4%9.3% | 2.7+131%7.1% | 2.4+124%5.1% | 1.9+115%3.9% | 1.6—2.9% | 1.2—2.8% | 1.1—2.2% | 0.9—1.8% | |
| Right-of-use (leased) assets | 2.4—5.4% | 2.4−20.9%5.4% | 2.6+16.6%4.6% | 2.8+16.9%4.0% | 2.9+155%3.7% | 3.1+144%9.2% | 2.2+62.9%5.8% | 2.4+60.2%5.0% | 1.1−25.6%2.3% | 1.3—2.3% | 1.4—3.3% | 1.5—3.1% | 1.5—3.1% | |
| Non-current assets | 8.0—17.9% | 8.0+1.7%17.9% | 7.9+20.7%13.9% | 7.9+26.2%11.4% | 8.1+97.7%10.3% | 7.9+106%23.6% | 6.5+85.6%16.9% | 6.3+80.4%13.4% | 4.1+24.1%8.1% | 3.8—6.9% | 3.5—8.4% | 3.5—7.3% | 3.3—6.6% | |
| Total assets | 45—100% | 45+33.9%100% | 56+46.0%100% | 69+48.3%100% | 78+55.4%100% | 33−40.1%100% | 39−8.0%100% | 47−1.8%100% | 50+0.9%100% | 56—100% | 42—100% | 48—100% | 50—100% | |
| Accounts payable | 1.7—3.7% | 1.7+9.0%3.7% | 2.0+13.1%3.5% | 1.3+0.1%1.8% | 1.8+34.3%2.2% | 1.5+63.8%4.6% | 1.7+162%4.5% | 1.3+33.5%2.7% | 1.3+117%2.6% | 0.9—1.7% | 0.7—1.6% | 0.9—2.0% | 0.6—1.2% | |
| Current liabilities | 9.6—21.6% | 9.6+6.4%21.6% | 9.4+28.2%16.7% | 11+39.5%15.4% | 11+48.9%13.8% | 9.1+30.2%27.2% | 7.4+51.1%19.0% | 7.7+27.5%16.4% | 7.3+54.9%14.4% | 7.0—12.5% | 4.9—11.6% | 6.0—12.6% | 4.7—9.4% | |
| Lease liabilities (non-current) | 2.0—4.4% | 2.0−21.5%4.4% | 2.0+24.6%3.6% | 2.2+23.8%3.2% | 2.4+247%3.0% | 2.5+219%7.5% | 1.6+79.3%4.2% | 1.8+73.0%3.8% | 0.7−35.8%1.4% | 0.8—1.4% | 0.9—2.2% | 1.0—2.2% | 1.1—2.1% | |
| Non-current liabilities | 3.5—7.8% | 3.5−13.6%7.8% | 3.4+15.2%6.0% | 3.5+14.7%5.0% | 3.5+89.9%4.5% | 4.0+109%12.1% | 3.0+43.4%7.7% | 3.0+43.4%6.5% | 1.9−10.0%3.7% | 1.9—3.5% | 2.1—4.9% | 2.1—4.5% | 2.1—4.1% | |
| Total liabilities | 13—29.4% | 13+0.2%29.4% | 13+24.5%22.8% | 14+32.5%20.5% | 14+57.3%18.3% | 13+47.2%39.3% | 10+48.8%26.7% | 11+31.7%22.9% | 9.1+35.0%18.1% | 8.9—16.0% | 6.9—16.5% | 8.1—17.1% | 6.8—13.5% | |
| Retained earnings | −330—−740% | −330—−740% | −316—−560% | −302—−436% | −291—−370% | −278—−833% | −265—−684% | −254—−542% | −244—−484% | −236—−425% | −229—−544% | −222—−465% | −216—−432% | |
| Shareholders' equity | 32—70.6% | 32+55.7%70.6% | 44+53.9%77.2% | 55+53.0%79.5% | 64+55.0%81.7% | 20−56.7%60.7% | 28−19.2%73.3% | 36−8.6%77.1% | 41−4.4%81.9% | 47—84.0% | 35—83.5% | 40—82.9% | 43—86.5% | |
| Total liabilities and equity | 45—100% | 45+33.9%100% | 56+46.0%100% | 69+48.3%100% | 78+55.4%100% | 33−40.1%100% | 39−8.0%100% | 47−1.8%100% | 50+0.9%100% | 56—100% | 42—100% | 48—100% | 50—100% | |
| Shares outstanding | 47—— | 47+44.1%— | 47+57.4%— | 44+63.6%— | 42+63.0%— | 33+29.2%— | 30+27.1%— | 27+21.8%— | 26+20.2%— | 25—— | 23—— | 22—— | 21—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 11−0.1%98.8% | 2.2*−30.9%125% | 2.1−22.9%61.9% | 2.8*+21.4%90.4% | 3.5*+45.1%140% | 3.2*+17.6%181% | 2.7+4.2%178% | 2.3*+42.3%120% | 2.4*+50.6%135% | 2.7*—157% | 2.6—173% | 1.6*—93.6% | 1.6*—104% | |
| Cash from operating activities | −41—−380% | −11*—−615% | −12—−363% | −9.3*—−297% | −8.6*—−342% | −8.3*—−469% | −8.8—−575% | −6.8*—−346% | −5.7*—−315% | −4.4*—−250% | −5.1—−335% | −4.2*—−237% | −4.0*—−260% | |
| Capital expenditure | −1.3—−11.5% | −0.3*—−18.6% | −0.2—−5.7% | −0.4*—−12.6% | −0.3*—−13.0% | −0.6*—−32.4% | −0.4—−23.5% | −0.3*—−16.0% | −0.4*—−23.3% | −0.5*—−27.3% | −0.2—−12.9% | −0.2*—−12.2% | −0.1*—−6.2% | |
| Cash from investing activities | −8.2−187%−75.2% | 15*+175%827% | 15+768%435% | −45*−648%−1433% | 7.6*—299% | 5.3*−3.3%299% | 1.7−64.7%111% | 8.2*—423% | −5.9*−193%−327% | 5.5*—317% | 4.8—319% | −0.0*—−2.0% | 6.4*—410% | |
| Shares issued | — | — | — | −38*−4008%−1198% | 38*—1507% | 0.2*−81.0%10.7% | 0.5—33.1% | 1.0r0*—49.5% | −1.0r0*—−53.3% | 1.0—57.5% | — | — | — | |
| Cash from financing activities | — | — | — | 0*−100%0.0% | 53*—2098% | 2.1*—120% | 0.5—33.1% | 1.6*—80.2% | −1.0*—−53.3% | — | — | 0*—0.0% | 0*—0.0% | |
| Change in cash | 3.6—33.6% | 3.8*—214% | 2.4—71.3% | −54*−1858%−1730% | 52*—2057% | −0.9*−105%−49.2% | −6.5—−427% | 3.1*—159% | −13*−648%−694% | 19*—1092% | −0.3—−16.6% | −4.2*—−238% | 2.3*—147% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What InspireMD, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- Other Countries$4 M45%+19%
- 🇺🇸 USA$1 M16%+4633%
- 🇮🇹 Italy$1 M14%+0.8%
- 🇩🇪 Germany$1 M14%+32%
- 🇵🇱 Poland$1 M12%+51%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where InspireMD, Inc. operates: 5 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇱 Israel | Headquarters | — |
| 🇺🇸 USA | 1 office | $1 M16% |
| 🇩🇪 Germany | $1 M14% | |
| 🇮🇹 Italy | $1 M14% | |
| 🇵🇱 Poland | $1 M12% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at InspireMD, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Marvin Slosman | $3.1 M | $1.3 M | $1.8 M | $207 |
| 2024Marvin Slosman | $3.3 M | $2.4 M | $1.6 M | $306 |
| 2023Marvin Slosman | $3.2 M | $5.9 M | $1.5 M | $327 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at InspireMD, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 11 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2025 | $40 M | Private placement after listing | $10 to $50 million | 18 | equity, options | SEC |
| May 2023 | $42 M | Private placement after listing | $10 to $50 million | 18 | equity, options | SEC |
| Jan 2013 | $3 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Oct 2012 | $2 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Apr 2012 | $11 M | Private placement after listing | $10 to $50 million | 6 | debt, options | SEC |
| Mar 2011 | $2 M | No. 1 | Under $2 million | 3 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How InspireMD, Inc. compares in Medical Devices
- Market cap$24 M · higher than 15% of 142
- Revenue$9 M · higher than 15% of 155
- Net margin-484.1% · higher than 3% of 144
- Revenue growth28.1% · higher than 81% of 104
- Price / sales2.3× · lower than 62% of 96
- Price / book0.4× · lower than 99% of 99
- FCF yield-150.9% · higher than 1% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| InspireMD, Inc.🇮🇱 | $24 M | — | -484.1% | +28.1% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at InspireMD, Inc.? Verify and update this profile — free
Show InspireMD, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.